Melbourne, Apr 14, 2008 (ABN Newswire) - Starpharma Holdings Ltd (ASX: SPL)(OTCQX: SPHRY) has filed a patent application for the use of SPL7013, the active ingredient in VivaGel(R), to inhibit hyaluronidase activity in the treatment or prevention of a number of diseases. The inhibitory activity was discovered during studies on the contraceptive activity of SPL7013, in which effects on hyaluronidase were examined due to the enzyme's involvement in the fertilization process.
